Date post: | 16-Feb-2018 |
Category: |
Documents |
Upload: | anggie-pradetya-maharani |
View: | 217 times |
Download: | 0 times |
of 43
7/23/2019 Insulin Initiation Promotional
1/43
@ 2015 Eli Lilly and Company
Insulin Initiation and IntensificationWhen Current Therapy Alone No Loner !ro"ides
Ade#uate $lycaemic Control
7/23/2019 Insulin Initiation Promotional
2/43
7/23/2019 Insulin Initiation Promotional
3/43
7
869ecti"es
/ Identify 6oth the clinical factors and the indi"idualised needs of yourpatient to determine the appropriate insulin therapy reimen
/Apply the clinical e"idence supportin the use of insulin analoue
mi,es to your current practice
7/23/2019 Insulin Initiation Promotional
4/43
5
Clinical Challene!erson -ith Type 2 &ia6etes on 8ral Therapies 6ut :6A1cIs ;*7 years
?e"ie- of patient lo6oo( sho-s !$
of ;*;1B*% mmolL D1>*22;%*7
mdLF o"er the past 2 months Weiht. 20; l6s D;5 (F
GHI. %1* (m2
Glood pressure. 1%55 mm: Current treatment. lipiide 10 m
J& metformin 1000 m GI& No reported hypolycaemia
Lab Results: !$. 10*7 mmolL D1>*2 mdLF 2hour !!$. 17*> mmolL D2B7*B mdLF
Total cholesterol. 7*> mmolL
D11*5 mdLF Trilycerides. 1*; mmolL D1B*1 mdLF A+T. 15 I'L
ALT. 1; I'L :6A1c. ;*7+50*
-ncretine//ect
7/23/2019 Insulin Initiation Promotional
8/43
7/23/2019 Insulin Initiation Promotional
9/4311
Basal insulinonly
(usually with oralagents)
Non-insulinregimens
Basal insulin +1
(mealtime)rapid-acting
insulininjection
Premixedinsulin twice
daily
Basal insulin +2
(mealtime)rapid-acting
insulininjections
low
mod.
ig
1
2
!+
Num"ero#
injections
$egimencomplexi
ty
%ore &exi"le 'ess&exi"le
lexi"ility
+e#uential Insulin +trateies in
Type 2 &ia6etes
Inucchi +E et al* Diabetes Care* 2012%5DBF.1%B71%>;*
7/23/2019 Insulin Initiation Promotional
10/4312
Treatment +trateies$lucose Triad
/ Treatment stratey should taret all % components
Ceriello A Colaiuri +* Diabet Med. 20025D10F.1151115B*
HbA1c
PP!*P!
7/23/2019 Insulin Initiation Promotional
11/43
7/23/2019 Insulin Initiation Promotional
12/43
7/23/2019 Insulin Initiation Promotional
13/43
7/23/2019 Insulin Initiation Promotional
14/431B
Gasal "s Healtime :yperlycaemia
in &ia6etes
Healthy
ArtistSs renderin 6ased on hypothetical lucose "alues*
?iddle HC* Diabetes Care* 1;;01%DBF.B>BBB*
When .nly 0ealtime Hyperglycaemia -s Corrected7asal hyperglycaemia 0ealtime hyperglycaemia
'2'' 1(''
3ime o/ %ay
14'' (5'' '2''
Plasma!lucose
"mmol#L$
111
&&
'
4)
1)6
(4
Change in A8C /rom healthy basal ;61 mmol#Lhr "15(& mg#dLhr$ 25=
7/23/2019 Insulin Initiation Promotional
15/43
7/23/2019 Insulin Initiation Promotional
16/43
A hi i :6A1 $ l
7/23/2019 Insulin Initiation Promotional
17/43
1;
Achie"in :6A1c $oalsComparison of !remi,ed Analoue Insulin -ith Gasal
Insulin Alone
Achieing HbA1c!oal "=$Hypoglycaemia: 7etween,
group Comparison
+tudy:6A1c
$oal
AnaloueHi, GI&
$larine!
"alue8"erall Nocturnal
!AI?!I1
DLillyF >*0< %0< 12< *002 No difference $larineRHi,
!AI?IN2DLillyF
>*0< 72< 1< *001 Hi,R$larine Hi,R$larine
INITIATE%DNo"oF
>*0< BB< 70< *001 Hi,R$larine Not reported
Uan(a=7D+anofi '+F
>*0< %;< 7;< *05;B Hi,R$larine Hi,R$larine
=:uman insulin mi, >0%0 "s larine V 8A&s D+' and HETF*Het K metformin No"o K No"o Nordis( 8A& K oral antidia6etes dru su K sulphonylurea*1* Halone UQ et al* Diabet Med* 200522D7F.%>7%1* 2* Halone UQ et al* Clin Ther. 20072BD12F.20%72077* %* ?as(in ! et al*DiabetesCare. 20052D2F.2B02B5* 7* Uan(a :' et al* DiabetesCare.20052D2F.25725;*
7/23/2019 Insulin Initiation Promotional
18/43
7/23/2019 Insulin Initiation Promotional
19/43
21
:umaloHi,25X D25< insulin lispro r&NA oriin3
in9ection >5< insulin lispro protamine suspensionF
/ In people -ithout dia6etes insulin secretion increases1and lucaonle"els are suppressed in response to a meal and G$ is maintained in
a narro- rane2
/ :umalo Hi,25 in a t-icedaily reimen pro"ides 6oth 6asal andrapidactin insulin -hich restores firstphase insulin response in
type 2 dia6etes and suppresses endoenous lucaon production%7
/ !remi,ed insulin tarets 6oth !$ and !!$ concentrations to lo-er:6A1c
/ ?ecent I& uidelines on postprandial control reflect the emerinimportance of postprandial G$ concentrations5
G$ K 6lood lucose I& K International &ia6etes ederation*
1* !olons(y Q+ et al* N Engl J Med* 1;%1D1;F.12%112%;* 2* 'ner ?:* N Engl J Med.1;>125DF.77%77;* %* Gruttomesso & et al* Diabetes.
1;;;7D1F.;;105* 7* ?oach ! Wood-orth U?* Clin Pharmacokinet* 200271D1%F.107%105>* 5* I&* A"aila6le at.
http.---*idf*or-e6datadocs$uideline4!H$4final*pdf* Accessed 2% Auust 201%*
7/23/2019 Insulin Initiation Promotional
20/43
7/23/2019 Insulin Initiation Promotional
21/43
7/23/2019 Insulin Initiation Promotional
22/43
27
Insulin &ose and Num6er of In9ections at Wee( 7
+&. standard de"iation
3reatment !roups
:umalo Hi,25nK1>>
GGTnK17
Hean insulin dose 'Q D+&F 0*>1 D0*75F 0*>1 D0*7>F
Hean num6er of daily in9ections D+&F 2*17 D0*>5F 2*25 D1*20F
In9ection reimen patients n D; D72*;F
T-o >7 D71*F 20 D10*;F
Three B% D%5*BF 7; D2B*BF
our %B D1;*BF
Go-erin et al* Diabet Med 20122;D;F.e2B%>2*
7/23/2019 Insulin Initiation Promotional
23/43
7/23/2019 Insulin Initiation Promotional
24/43
7/23/2019 Insulin Initiation Promotional
25/43
7/23/2019 Insulin Initiation Promotional
26/43
7/23/2019 Insulin Initiation Promotional
27/43
7/23/2019 Insulin Initiation Promotional
28/43
7/23/2019 Insulin Initiation Promotional
29/43
7/23/2019 Insulin Initiation Promotional
30/43
7/23/2019 Insulin Initiation Promotional
31/43
Hu"alog 4i=%5 >/ $s >asal nsulin ?largine *nce /aily
7/23/2019 Insulin Initiation Promotional
32/43
%7
Hu"alog 4i=%5 >/ $s >asal nsulin ?largine *nce /aily@ Hu"alog *nce /ailyu""ary
/ 0oninferiority ( oulation): and then sueriority (TT oulation): of Hu"alog 4i=%5>/ $s. >>T was shown in ter"s of change in HbA1cat %' wees
/ 4ean blood glucose: glycae"ic $ariability: o$erall tolerability: and hyoglycae"ic
eisodes er atient#year did not show signiBcant di
7/23/2019 Insulin Initiation Promotional
33/43
%5
nitiating Theray with Hu"alog 4i=%5
7tart wit low dose and increase gradually1
0nsulin-na98e patients tart as 1& E subcutaneously () before breafast
and e$ening "eals1
Patients already on once-daily insulin alculate total daily dose Total daily dose F % ?i$e G before breafast and G before e$ening "eal
OAD recommendation: 4aintain at least "etfor"in 1#1.5 g-day in di$ided doses
to sulhonylureaBG measurements:
4onitor re#breafast (fasting) and re#e$ening "eal >?e$ery ,#' days
;*A/s to be used in accordance with the locally aro$ed acage insert. o"e *A/s "ay be contraindicated. hysicians andatients should decide if additional >? "easure"ents "ay be needed.
1. Hirsch >: et al. Clin Diabetes %&&5%,(%)I78#86. %. /J tas force for clinical guidelines. A$ailable athttI--www.idf.org-sites-default-Bles-/J#?uideline#for#Tye#%#/iabetes.df. Accessed %, August %&1,.
atients with Tye % /iabetes on ntensi$e nsulin
7/23/2019 Insulin Initiation Promotional
34/43
%B
atients with Tye % /iabetes on ntensi$e nsulinTheray Achie$e ?lycae"ic ontrol Esing 5&3>asal and 5&3 >olus (rerandial) nsulin
/ n indi$iduals withoutdiabetes: endogenous
basal insulin secretion
accounts for
aro=i"ately 5&3 of
total daily insulin1
/ atients with tye %
diabetes on intensi$e
insulin theray
regi"ens can achie$e
glycae"ic control using5&3 basal and 5&3
bolus insulin%
;/oses adKusted to achie$e target rerandial and bedti"e >? le$els.1. olonsy L: et al.J Clin Invest.198881(%)I''%#''8. %. Her"an MH: et al. Diabetes Care.%&&5%8(7)I1568#157,.
%ean3o
tala
ily
0nsu
lin
ose
(un
its
)
Basal ose Bolus ose
P.!P.!
,1,*
, ,,
144
,4
4
:ontinuous su"cutaneous insulin in#usion(n,1)%ultiple daily injections (n,*)
0nsulin ose at 5ndpoint2
7/23/2019 Insulin Initiation Promotional
35/43
7/23/2019 Insulin Initiation Promotional
36/43
li i l h ll
7/23/2019 Insulin Initiation Promotional
37/43
%;
:ase Presentation; AgeI 5% years /uration of tye % diabetesI 7 years Qe$iew of atient logboo shows J? of 9.9#
16., ""ol- (178.%#%9,.' "g-d) o$er theast % "onths
MeightI %&9 lbs (95 g) >4I ,1.8 g-"%
>lood ressureI 1,5-85 ""Hg urrent treat"entI gliiSide 1& "g D/:
"etfor"in 1&&& "g >/ J?I 1&.' ""ol- (187.% "g-d) %#hour ?I 1'.7 ""ol- (%6'.6 "g-d)
HbA1cI 9.'3
linical hallengeerson on *ral Theraies but HbA1cs 9.'3
Patient Perspecti8e; Mants to i"ro$e glycae"ic control and is willing to add an inKectable
theraybut wants to "ini"ise the nu"ber of inKections
Has a fairly redictable daily routine: including "eal co"osition
7/23/2019 Insulin Initiation Promotional
38/43
7/23/2019 Insulin Initiation Promotional
39/43
7/23/2019 Insulin Initiation Promotional
40/43
re"i=ed nsulin Analogues $s
7/23/2019 Insulin Initiation Promotional
41/43
77
re"i=ed nsulin Analogues $s>asal nsulin Analogueshange in HbA1cat ndoint in ' QTs
re"i=ed nsulinI %5#,&3 raid#acting analogue Vnsulin#e=erienced atients. ;PW.&1 ;;PW.&&1.>As ! bihasic insulin asart 7&-,& QT ! rando"ised controlled trial.
/eri$ed fro" 1. Qasin : et al. Diabetes Care.%&&5%8(%)I%6%65. %. Hol"an QQ: et al. N Engl J Med.%&&7,57(17)I1716#17,&.,. 4alone RL: et al. Clin Ther.%&&'%6(1%)I%&,'#%&''. '. 4alone RL: et al. Diabet Med.%&&5%%(')I,7'#,81.
:
ange
in."/
1c
(6)
Basal insulin
Premixed insulin
0nsulin
7/23/2019 Insulin Initiation Promotional
42/43
7/23/2019 Insulin Initiation Promotional
43/43